Press release
Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk
"Type 2 Diabetes Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.
The Type 2 Diabetes Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, spanning from pre-clinical development to market availability. It includes a comprehensive overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development aspects such as technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details.
Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight [https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key takeaways from the Type 2 Diabetes Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years.
*
Type 2 Diabetes companies working in the treatment market are Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others, are developing therapies for the Type 2 Diabetes treatment
*
Emerging Type 2 Diabetes therapies in the different phases of clinical trials are- Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years.
*
In May 2026, Novo Nordisk announced that Ozempic Registered (semaglutide) tablets in 1.5 mg, 4 mg, and 9 mg strengths will become available in the U.S. for adults with type 2 diabetes starting Monday, May 4. Ozempic Registered is currently the only FDA-approved oral peptide GLP-1 therapy indicated for adults with type 2 diabetes to help improve blood glucose levels alongside diet and exercise, while also lowering the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death in high-risk patients. Oral semaglutide has previously been marketed for type 2 diabetes under the brand name Rybelsus Registered , which is offered in a different formulation and dosage range.
*
In March 2026, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Awiqli Registered (insulin icodec-abae) injection 700 units/mL, making it the first and only once-weekly long-acting basal insulin for adults with type 2 diabetes. The therapy is approved for use alongside diet and exercise to help improve glycemic control. This approval introduces the only once-weekly basal insulin treatment option currently available, highlighting the growing focus on personalized diabetes care and the need for therapies that better align with individual patient lifestyles, routines, and treatment preferences.
*
In April 2025, Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company specializing in the development of novel peptide-based therapies, has announced the enrollment of the first participant in its Phase 2b ZUPREME-2 trial. This study targets individuals with overweight or Type 2 Diabetes and type 2 diabetes, evaluating the efficacy and safety of once-weekly subcutaneous doses of petrelintide, a long-acting amylin analogue, in comparison to a placebo.
*
In February 2025, Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery system, now approved for use in individuals with type 2 diabetes.
*
In February 2025, Sotagliflozin, which has FDA approval for treating type 2 diabetes and kidney disease, has demonstrated a substantial reduction in the risk of heart attack and stroke among high-risk patients, presenting a promising option for cardiovascular protection.
*
In January 2025, The FDA approved a new indication for semaglutide to help lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, as announced by Novo Nordisk.
Type 2 Diabetes Overview
Type 2 Diabetes is a chronic metabolic condition where the body becomes resistant to insulin or doesn't produce enough insulin, leading to high blood sugar levels. It usually develops in adults but is increasingly seen in younger people due to Type 2 Diabetes and sedentary lifestyles. Unlike Type 1 diabetes, it is often linked to lifestyle factors and can sometimes be managed through diet, exercise, oral medications, or insulin. If left uncontrolled, Type 2 diabetes can cause complications like heart disease, kidney problems, nerve damage, and vision issues. Regular monitoring and healthy lifestyle changes are key to management.
Discover breakthrough Type 2 Diabetes therapies transforming future metabolic disease treatment. Explore Type 2 Diabetes Clinical Trials [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:
*
Tirzepatide/LY3298176: Eli Lilly and Company
*
Danuglipron: Pfizer
*
RGT001-075: Regor Pharmaceuticals Inc.
*
AZD0186: AstraZeneca
*
ECC5004: Eccogene
*
PF-07081532: Pfizer
*
XW014: Sciwind Biosciences USA Co., Ltd.
*
MN-001: MediciNova
*
SPI-62: Sparrow Pharmaceuticals
*
HTD1801: HighTide Biopharma Pty Ltd
*
Semaglutide: Novo Nordisk A/S
*
BMF-219: Biomea Fusion Inc.
*
ALT-801: Altimmune, Inc.
*
MBL949: Novartis
*
LY3457263: Eli Lilly and Company
*
AMG 133: Amgen
*
DD01: Neuraly, Inc.
*
CT-868: Carmot Therapeutics, Inc.
*
IVA337: Inventiva Pharma
*
INV-202: Inversago Pharma Inc
*
AT-001: Applied Therapeutics, Inc.
Type 2 Diabetes Route of Administration
Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Intravenous
*
Subcutaneous
*
Parenteral
*
Topical
Type 2 Diabetes Molecule Type
Type 2 Diabetes Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Type 2 Diabetes Pipeline Therapeutics Assessment
*
Type 2 Diabetes Assessment by Product Type
*
Type 2 Diabetes By Stage and Product Type
*
Type 2 Diabetes Assessment by Route of Administration
*
Type 2 Diabetes By Stage and Route of Administration
*
Type 2 Diabetes Assessment by Molecule Type
*
Type 2 Diabetes by Stage and Molecule Type
DelveInsight's Type 2 Diabetes Report covers around 80+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Type 2 Diabetes Therapeutics Market include:
Key companies developing therapies for Type 2 Diabetes are - Novo Nordisk, Jiangsu Hengrui Medicine, Melior Pharmaceuticals, Adocia, Pfizer, AgeX Therapeutics, CarmotTherapeutics, Genexine, Inc., OPKO Health, Inc., VitNovo, Inc., Sciwind Biosciences, Caelus Health, SCOHIA PHARMA, Ionis Pharmaceuticals, Eli Lilly and Company, Oramed Pharmaceuticals, AstraZeneca, Aerami Therapeutics, Viking Therapeutics, VTV Therapeutics, AptamiR Therapeutics, Avolynt, Inc., Suzhou Yabao Pharmaceutical, CONJUCHEM, LLC., Hua Medicine, REMD Biotherapeutics, Novmeta Pharma, Afimmune Limited, Xeris Pharmaceuticals, Akros Pharma Inc., and others.
Type 2 Diabetes Pipeline Analysis:
The Type 2 Diabetes pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.
*
Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Type 2 Diabetes Pipeline Market Drivers
*
Increasing prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Type 2 Diabetes Market.
Type 2 Diabetes Pipeline Market Barriers
*
However, side-effects associated with the treatment of Type 2 Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Type 2 Diabetes Market growth.
Scope of Type 2 Diabetes Pipeline Drug Insight
*
Coverage: Global
*
Key Type 2 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
*
Key Type 2 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
*
Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies
*
Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers
Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Type 2 Diabetes Report Introduction
2. Type 2 Diabetes Executive Summary
3. Type 2 Diabetes Overview
4. Type 2 Diabetes- Analytical Perspective In-depth Commercial Assessment
5. Type 2 Diabetes Pipeline Therapeutics
6. Type 2 Diabetes Late Stage Products (Phase II/III)
7. Type 2 Diabetes Mid Stage Products (Phase II)
8. Type 2 Diabetes Early Stage Products (Phase I)
9. Type 2 Diabetes Preclinical Stage Products
10. Type 2 Diabetes Therapeutics Assessment
11. Type 2 Diabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Type 2 Diabetes Key Companies
14. Type 2 Diabetes Key Products
15. Type 2 Diabetes Unmet Needs
16 . Type 2 Diabetes Market Drivers and Barriers
17. Type 2 Diabetes Future Perspectives and Conclusion
18. Type 2 Diabetes Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=type-2-diabetes-pipeline-2026-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-ionis-pharma-eli-lilly-oramed-pharma-astrazeneca-novo-nordisk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk here
News-ID: 4526529 • Views: …
More Releases from ABNewswire
Tundrr Carbon-Based Soil Conditioner for Global Buyers: Specification-Led Sourci …
Tundrr Carbon-Based Soil Conditioner provides global buyers with a specification-led soil-improvement sourcing option from China. Formulated with greater than or equal to 35% organic matter, greater than or equal to 25% biochar, plus defined calcium, silicon, and magnesium content, it is designed for soil-structure and acidic-soil management programs. Tundrr supports quality control and export coordination for agricultural buyers.
As growers, agricultural distributors, private-label programs, and soil-management projects place greater emphasis on…
ROAM Roof & Solar Launches Radiant Barrier Service as Central Texas Homeowners S …
As ERCOT forecasts record power demand across Texas this summer, Belton-based ROAM Roof & Solar has launched a radiant barrier program backed by U.S. Department of Energy testing - aimed at helping homeowners reduce attic heat and ease the strain on rising electric bills.
BELTON, Texas - July 30, 2026 - ROAM Roof & Solar, a veteran-owned roofing, siding, gutters, solar, and waterproofing company, today announced the launch of its radiant…
Sunbird Carpet Cleaning of Columbia Says One Red Wine Spill Still Stands Out Aft …
The call came on a Tuesday morning from a homeowner in Columbia's Hickory Ridge neighborhood. Friends had gathered over the weekend, someone tipped over a glass of Cabernet, and red wine soaked into a light-colored living room carpet. The family reached for paper towels, club soda, and a grocery-store stain remover. Three days later, the stain had grown darker, the carpet felt stiff, and the spill had spread well beyond…
Baltimore Carpet & Upholstery Finds a Home Office Frozen in Time Beneath One Des …
The desk hadn't moved in nearly five years. When a Roland Park homeowner finally rolled it aside before a scheduled carpet cleaning, technicians from Baltimore Carpet & Upholstery uncovered something few people expect to see: a detailed record of thousands of workdays preserved in the carpet since 2020.
A software engineer living in Baltimore's Roland Park neighborhood scheduled a carpet cleaning after deciding to reclaim a spare bedroom that had served…
More Releases for Type
L-type, J-type, T-type, and I-type anchor bolts: How to select the correct type …
Choosing the right anchor bolt for your construction or industrial project can feel like navigating a maze, especially when you are looking at four different shapes and wondering which one will actually hold your structure securely. If you are new to specifying foundation bolts, you probably have three big concerns running through your mind. First, will the bolt I choose actually resist the pull-out forces from wind or vibration, or…
Pressure Pumping Market 2028 By Type, Well Type, Resource Type and Geography
The Insight Partners delivers well-researched industry-wide information on the Pressure Pumping market. It provides information on the market's essential aspects such as top participants, factors driving Pressure Pumping market growth, precise estimation of the Pressure Pumping market size, upcoming trends, changes in consumer behavioral pattern, market's competitive landscape, key market vendors, and other market features to gain an in-depth analysis of the market. Additionally, the report is a compilation of…
Lawn Mowers Market Analysis By Type, End User, Product Type, Fuel Type, Engine P …
Lawn Mowers Market Analysis By Type(Manual, Electric, Petrol, Robotic), By End User(Residential, Commercial), By Product Type(Walk behind Movers, Ride on Movers, Stand on Movers), By Fuel Type(Gas Powered, Propane Powered), By Engine Power(Less than 15 hp, Between 15hp and 30 hp, More than 30 hp), By Blade Type(Cylinder, Standard, Mulching, Lifting), By Drive Type(AWD, FWD, RWD), By Application(Residential, Professional landscaping, Golf Course, Government), By Distribution Channel(Retail Store, Online Website) &…
Automotive Exhaust System Component Market Type, Fuel Type, Treatment Device, Ve …
Automotive Exhaust System Component Market
This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering
Tenneco
Faurecia
Eberspacher
Boysen
Sango
HITER
Yutaka Giken
Calsonic Kansei
Magneti Marelli
Benteler
Sejong Industrial
Katcon
Futaba
Wanxiang
Bosal
Harbin Airui
Dinex
Catar
DSM
Get Sample PDF including full TOC, Tables and Figures @ https://www.ozonemarketreports.com/automotive-and-transportation/global-automotive-exhaust-system-components-market-professional-survey-report-2019/59563
On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
Exhaust Manifold
Exhaust Pipe
Catalytic Converter
Exhaust Temperature Sensor
Car Muffler
Exhaust…
Automotive Electric Vacuum Pump Market By Type Diaphragm Type, Swing Piston Type …
Automatic electric vacuum pump is a device that gets the drive from the camshaft in the engine. It can also be run by alternator shaft in some designs. It’s an added benefit to any engine, which has high performance. The primary function of an automatic electric vacuum pump is to drain out the air from brake booster tank hence creating the vacuum, which in turn can be used for application…
Marine Composites Market |By Type |Resin Type|Vessel Type|Fiber Type |Region Ana …
The report includes market segmentation by composites type (metal matrix composite, ceramic matrix composite, polymer matrix composite); polymer matrix composite by fiber type (glass fiber, carbon fiber, others); polymer matrix composite by resin type (polyester, vinyl ester, epoxy, thermoplastic, others); vessel type (power boats, sailboats, cruise ships, others); and region (North America, Europe, APAC, Latin America, MEA).
Download Latest Free PDF Sample Brochure of “Marine Composites Market” With Detailed TOC…
